Role of TLR-2 in the Activation of Nuclear Factor kappa B by Oxidative Stress in Cardiac Myocytes*

Stefan Frantz, Ralph A. Kelly, and Todd BourcierDagger

From the Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115

Received for publication, October 6, 2000, and in revised form, November 15, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Growing evidence from patients with heart failure and from experimental animal models implicates effectors of innate immunity in the pathogenesis of this syndrome. The expression of the innate immunity signaling protein, Toll-like receptor 4 (TLR4), is increased in cardiac myocytes in situ and in failing myocardium, but the mechanism by which TLRs may be activated in the failing heart remains unclear. We report that TLR2, which is expressed in cardiac myocytes, participates in the response of these cells to oxidative stress, a major contributor to the pathogenesis of cardiac dysfunction. Hydrogen peroxide increased nuclear factor kappa B (NF-kappa B) activation in Chinese hamster ovary fibroblasts that overexpress TLR2 but not in normal or TLR4-overexpressing Chinese hamster ovary cells, an effect that was abrogated by an alpha -TLR2 antibody. In neonatal rat ventricular myocytes, the alpha -TLR2 antibody inhibited hydrogen peroxide-induced nuclear translocation of NF-kappa B and activator protein-1 (AP-1). Inhibition of TLR2 had no effect on tumor necrosis factor alpha -induced NF-kappa B or AP-1 activation, on the DNA binding of the basal transcription factor Oct-1, or on hydrogen peroxide-induced phosphorylation of p38 MAP kinase. Importantly, oxidative stress-induced cytotoxicity was enhanced by blocking TLR2. Given the importance of cytotoxicity and apoptosis to the pathology of the ischemic heart, an anti-apoptotic effect of TLR2 in cardiac myocytes exposed to elevated levels of ROS may limit further cardiac dysfunction.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The mammalian toll-like receptors (TLRs)1 are a recently recognized family of proteins implicated in directing innate immune responses by components of diverse pathogens (1, 2). So far, six human TLRs have been cloned (3, 4), and several others are suggested to be present. Medzhitov et al. (5) were the first to show that constitutively active TLR4 induces the activation of NF-kappa B with the subsequent expression of IL-1, IL-6, IL-8, and the costimulatory molecule B7.1. Active TLR4 can also induce c-Jun NH2-terminal kinase (JNK) (6). The role of TLRs as innate immunity receptors has been extensively studied. TLR2, for example, is activated by components of Gram-positive bacteria (7), mycobacteria (8, 9), and Borrelia (10). The most convincing evidence exists for a role of TLR4 in the recognition of bacterial LPS (lipopolysaccharides). Mice with either a spontaneous mutation of the TLR4 gene or targeted disruption of the gene have no response to lipopolysaccharides and are thus resistant to endotoxic shock (11-13). In contrast, mice with targeted disruption of TLR2 have no deficit in the recognition of Gram-negative bacteria (14). Interestingly, missense mutations affecting the extracellular domain of the TLR4 receptor are associated with a blunted response to inhaled LPS in humans (15).

Most studies have focused on TLR expression and function in mononuclear cells and monocyte-like cell lines; however, TLRs differentially exhibit a wider pattern of tissue expression, including the lung, heart, and brain (2). Thus, TLRs may additionally serve as pro-inflammatory receptors in cell types without a dedicated immune function. TLR4, for example, is expressed by human dermal endothelial cells and can activate NF-kappa B (16). We previously demonstrated (17) that TLR4 is expressed in the heart and that injured human and murine myocardium exhibit focal areas of intense TLR4 expression. The reason for this differential expression of TLR4, as well as the function of TLR4 in the injured heart, in the absence of infection, remains unknown. Although the identity of endogenous ligands, analogous to Drosophila spatzle, for the vertebrate TLRs remains elusive, a recent report suggests that the stress-associated factor heat-shock protein 60 signals through TLR4 (18). Thus, innate immunity receptors may not only be activated by microorganisms, but also by endogenous signals that originate from injured cells that emanate "danger signals" (19).

Oxidative stress in the post-ischemic heart has been identified as an important event in myocardial dysfunction, linked to both myocardial hypertrophy and apoptosis. Oxidative stress is known to induce cell death by apoptotic and necrotic pathways in isolated cardiac myocytes (20) and to trigger pro-inflammatory signaling pathways that activate NF-kappa B and AP-1 transcription factors (21, 22). Numerous mechanisms are suggested to underlie these effects of hydrogen peroxide, which are likely to be cell type-specific. Herein, we show a requirement of TLR2 for the activation of NF-kappa B and AP-1 by hydrogen peroxide and provide evidence that TLR2 imparts an anti-apoptotic effect in stressed or injured cardiac myocytes.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Chemicals-- Human recombinant TNFalpha was purchased from Endogen (Woburn, MA). All other chemicals, including hydrogen peroxide, were purchased from Sigma Chemical Co. unless noted otherwise.

Cell Lines, Cell Isolation, and Culture-- Chinese hamster ovary K1 (CHO-K1) fibroblasts were obtained from D. T. Golenbock (23). The cell lines stably express CD-14, an NF-kappa B-dependent CD25 reporter construct, and empty vector (CHO/control), human TLR2 (CHO/TLR2), or human TLR4 (CHO/TLR4). The cells were maintained as described (23). Cells were stimulated as indicated in Ham's F-12 medium containing 10% fetal calf serum (Life Technologies, Inc.).

Neonatal rat ventricular myocytes (NRVM) were isolated from 1-day-old Harlan Sprague-Dawley pups as described (17). NRVM were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (Life Technologies, Inc.). After 48 h, the medium was changed to Dulbecco's modified Eagle's medium /F-12 medium (Life Technologies, Inc.) containing 1% insulin, transferrin, selenium media supplement (ITS, Sigma) with antibiotics. Treatments were initiated 12 h later.

CHO fibroblasts and NRVM were pretreated with a TLR-2 blocking antibody raised to a peptide that maps to the amino terminus of human TLR2 (5 or 10 µg/ml, number N-17, Santa Cruz Biotechnologies Inc., Santa Cruz, CA) for 1 h prior to addition of experimental treatments.

RT-PCR-- Expression of rat TLR 1-6 were assessed using total RNA by RT-PCR from NRVM after treatment with deoxyribonuclease 1 (Life Technologies, Inc.) as described in the manufacturer's protocol. cDNA was generated using Superscript II (Life Technologies, Inc.). As a negative control, no reverse transcriptase was added. PCR primers were for TLR1 (383 bp) 5'-AAA CGG TCT CAT CCA CGT TC and 5'-GAG CAA TTG GCA GCA CAC TA, for TLR 2 (298 bp) 5'-GGC CAG CAA ATT ACC TGT GT and 5'-TTC TCC ACC CAG TAG GCA TC, for TLR3 (469 bp) 5'-TGC CTT GGT CCC AAG CCT TCA ACG A and 5'-TGG CCC GAA AAC CTT CTT CTC AAC GGA, for TLR4 and the positive control (555 bp) 5'-CGC TTT CAG CTT TGC CTT CAT TAC and 5'-TGC TAC TTC CTT GTG CCC TGT GAG, for TLR5 (280 bp) 5'-AAG AGG GAA ACC CCA CAG AA and 5'-GGG GAC TAA GCC TCA ACT CC, and for TLR6 (593 bp) 5'-GGG GCT TTC CTC TGT CTC TA and 5'-CCC AAG TTT CAA GTT TTC ACA T. All PCR products were size-fractionated by a 2% agarose gel electrophoresis, and DNA bands were visualized by staining the gel with ethidium bromide.

Immunocytochemistry-- NRVMs were grown in chamber slides (Nunc, Naperville, IL). Cells were fixed with 4% formaldehyde in phosphate-buffered saline (PBS) for 10 min, washed, and exposed for 10 min to 0.3% Triton X-100 in PBS. After 10-min exposure to 0.1 M glycine in PBS, cells were blocked with 5% normal horse serum (Vector Laboratories, Burlingame, CA). Cells were labeled by the sequential application of the primary human TLR2 antibody, an anti-goat FITC-conjugated secondary antibody, a second primary rat caveolin 3 antibody (Transduction Laboratories, Lexington, KY), and a secondary Alexa 568-tagged anti-mouse antibody (Molecular Probes, Eugene, OR). Images were taken with a confocal laser scanning microscope (model MRC-1024, Bio-Rad Laboratories, Hercules, CA). The specificity of the primary goat polyclonal anti-hTLR2 antibody was assessed by preincubating the antibody with the hTLR2 matching peptide (Santa Cruz Biotechnologies Inc.).

Western Blotting-- For Western blots, cells were harvested in SDS sample buffer (62.5 mM Tris base, 2% SDS, 10% glycerol, 50 mM dithiothreitol). After cell extracts were boiled, equal amounts of the denatured protein per lane were loaded, separated on a 7.5 or 15% SDS-polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes. After blocking with 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBST), membranes were incubated with anti-hTLR2 (1:500) or anti-p38/phospho p38 (1:100, New England BioLabs, Boston, MA) overnight. After several washes the membranes were incubated for 1 h with a matching secondary antibody (Jackson Laboratories, Bar Harbor, ME; 1:10,000 dilution). After additional washes, membranes were incubated with a chemiluminescent (Renaissance, PerkinElmer Life Sciences, Boston, MA) and autoradiographed.

Flow Cytometric Analysis of NF-kappa B Activity-- CHO cells were stimulated as indicated in Ham's F-12 medium supplemented with 10% fetal calf serum for 24 h. Cells were harvested with trypsin-EDTA and labeled with an FITC CD25 monoclonal antibody (Becton Dickinson Immunocytometry Systems, San Jose, CA). Analysis was performed on 10,000 cells/sample using a FACscan.

Electromobility Shift Assay-- Cells were treated as indicated for 2 h following pretreatment with the blocking antibody for 1 h. Electromobility shift assays were performed as described elsewhere (24). Binding reactions were performed with 10 µg of nuclear protein. The binding reactions for AP-1 activity contained an additional 5 mM MgCl2. Control reaction mixtures contained a 100-fold excess of unlabeled oligonucleotide and were incubated with nuclear extracts as indicated. DNA complexes were separated on a 5% nondenaturing polyacrylamide gel in Tris-borate EDTA buffer. NF-kappa B, AP-1, and Oct-1 oligonucleotides were purchased from Santa Cruz Biotechnologies.

Flow Cytometry Analysis for the Detection of Sub-G1 and Phosphatidylserine-- FACS was used to detect cells with a hypodiploid content of DNA and surface expression of phosphatidylserine by staining with FITC-annexin V. NRVM were collected by trypsinization, pooled with nonattached cells, and fixed with ice-cold 70% ethanol/PBS. After being rinsed with PBS, cells were incubated with a propidium iodide (20 µg/ml) solution containing RNase A (5 Kunitz units/ml) at room temperature for 30 min. NRVM in the sub-G1 region were identified using ModFit software, and data are expressed as the percentage of cells in sub-G1. For detection of surface phosphatidylserine, NRVM were collected by trypsinization and directly stained with FITC-annexin V, according to the manufacturer's direction (CLONTECH, Palo Alto, CA). FACS analysis was performed on 10,000 cells/sample using a FACscan cytometer (Becton Dickinson).

Statistical Analyses-- All replicate data are expressed as mean and standard error of mean. In experiments with comparison of treatments, an unpaired Student's t test was performed. In experiments with time courses, analysis of variance was used followed by Fisher's post-hoc test. Statistical significance was achieved when p <=  0.05. Statistical analyses were carried out using StatView statistics program (Abacus Concepts, Inc., Berkley, CA).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Expression Pattern of TLRs in Neonatal Rat Cardiac Myocytes-- Six human TLR cDNAs have been identified (3, 4). However, their distribution in cardiac tissue is unknown. TLR2, TLR3, TLR4, and TLR6 were detectable by reverse transcription-PCR in primary NRVM cultures (Fig. 1a). Signals for TLR1 and TLR5 were absent in cardiac tissue, whereas spleen showed the expected TLR1 and TLR5 bands (data not shown).



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   TLR expression in neonatal rat ventricular myocytes. a, TLR2, TLR3, TLR4, and TLR6 are expressed in neonatal rat cardiac myocytes, measured by RT-PCR. No signal could be detected for TLR1 and TLR5, although both were detectable in spleen as a control tissue. The ± symbol indicates the presence/absence of reverse transcriptase prior to glyceraldehyde-3-phosphate dehydrogenase amplification. b, polyclonal TLR2 antibody detected selectively TLR2 in TLR2-overexpressing CHO fibroblasts but not in control or TLR4-overexpressing cells. c, immunocytochemistry confirmed TLR2 expression in neonatal rat cardiac myocytes (green fluorescence). Caveolin 3 was used as a myocyte marker (red fluorescence). Absorption with the peptide used to generate the primary antibody was used as control.

We previously reported that TLR4 protein is expressed by cardiac myocytes (17) but did not explore the expression of TLR2. Using a polyclonal TLR2 antibody, a single band was detected in a TLR2-overexpressing cell line (CHO/TLR2) but not in control (CHO/control) or TLR4-overexpressing (CHO/TLR4) cell lines. A corresponding band could be detected in lysates of neonatal cardiac myocytes (Fig. 1b). Immunocytochemical staining with the same antibody confirmed the expression of TLR2 in myocytes (Fig. 1c). Primary isolates of neonatal rat ventricular myocytes in vitro exhibited sarcolemmal membrane staining that was inhibited by preincubation with the corresponding TLR2 peptide used to generate the primary antibody. That TLR2-positive cells also expressed caveolin 3 verified their identity as cardiac myocytes.

TLR2 Enhances NF-kappa B Activity after Stimulation with Hydrogen Peroxide in a CHO Cell Line-- Reactive oxygen intermediates play a key role in cardiac damage following ischemic injury. To investigate a potential role of TLRs in the response to oxidative stress, TLR-expressing CHO cell lines were used. CHO fibroblasts do not express mRNA for full-length and functional TLR2 (25). The obtained cell lines have previously been characterized (23) and overexpress CD14, inducible membrane CD25 under the control of an NF-kappa B promoter, and empty vector (CHO/control), human TLR2 (CHO/TLR2), or human TLR4 (CHO/TLR4). Oxidative stress was induced by the application of hydrogen peroxide (1 mM). The activity of NF-kappa B could be monitored by expression of membrane CD25 by flow cytometric analysis. Untreated cells showed nearly equal expression of CD25. TNFalpha increased CD25 expression evenly in the CHO/control, CHO/TLR2, and CHO/TLR4 lines after 24 h of treatment. However, application of hydrogen peroxide consistently increased NF-kappa B activity in the CHO/TLR2 cells to a greater extent than in the CHO/control and CHO/TLR4 cell lines (Fig. 2a). In addition, hydrogen peroxide increased nuclear translocation of NF-kappa B in the CHO/TLR2 line, but was ineffective in the CHO/control line after 2 h of treatment, as measured by EMSA. There was no difference in the amount of nuclear NF-kappa B for TNFalpha -treated cells (Fig. 2b). Moreover, a 1-h preincubation with a TLR2 blocking antibody but not control IgG (data not shown) completely abrogated the nuclear translocation of NF-kappa B. The binding of Oct-1, a transcription factor that is constitutively expressed, was unchanged by the treatment (Fig. 2c). CHO cells showed a high basal level of nuclear AP-1 by EMSA without treatment, and was unchanged by preincubation with the TLR2 antibody or treatment with hydrogen peroxide (data not shown). These results suggest that TLR2 enhances hydrogen peroxide-induced activation of NF-kappa B.



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   TLR2 is involved in hydrogen peroxide-induced NF-kappa B activation in CHO fibroblast. a, TLR2-overexpressing CHO cells showed an increase in NF-kappa B activity, as measured by CD25 expression, when compared with control and TLR4-overexpressing cells. No difference could be detected in unstimulated or TNFalpha -stimulated cells. All experiments were done in triplicate. b, electrophoretic mobility shift assays could detect an increase in nuclear translocation of NF-kappa B after stimulation with H2O2 (1 mM) in TLR2-overexpressing CHO fibroblasts when compared with the control cell line. c, NF-kappa B translocation could be suppressed by pretreatment with a TLR2 blocking antibody, as measured by EMSA, whereas DNA binding of the constitutively expressed transcription factor Oct-1 was unchanged.

TLR2 Is Involved in Nuclear Translocation of NF-kappa B after Oxidative Stress in Neonatal Rat Cardiac Myocytes-- To test whether TLR2 participates in the response to oxidative stress in cardiac myocytes, NRVM were preincubated with the blocking TLR2 antibody for 1 h and then treated with hydrogen peroxide for another 2 h. As for the CHO cells, the TLR2 blocking antibody could completely abrogate the nuclear translocation of NF-kappa B (Fig. 3a), whereas preincubation with control IgG was without effect. NF-kappa B activation by TNFalpha was unchanged by treatment with the TLR2 blocking antibody. Similar to NF-kappa B, AP-1 induction by hydrogen peroxide could be blocked by the TLR2 blocking antibody, but not AP-1 induction by TNF-alpha . The constitutively expressed Oct-1 was unchanged by the treatments.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   TLR2 is involved in hydrogen peroxide-induced NF-kappa B activation in neonatal rat ventricular myocytes. a, pretreatment with a TLR2 blocking antibody inhibited nuclear translocation of NF-kappa B and AP-1 after a 2-h treatment with hydrogen peroxide (left panels) but had no influence on the constitutively expressed transcription factor Oct-1 or on nuclear translocation of NF-kappa B after treatment with TNF (middle panels). A nonimmune IgG antibody (NI IgG) did not affect hydrogen peroxide-induced NF-kappa B translocation (right panel). b, hydrogen peroxide-induced phosphorylation of p38 MAP kinase, shown in the top panel using an antibody specific for phosphorylated p38 MAPK, is unaffected by the anti-TLR2 blocking antibody. The lower panel shows equal amounts of p38 MAPK in each lane. All experiments were done in triplicate.

Oxidative stress is also known to rapidly induce the phosphorylation of p38 MAPK in cardiac myocytes (26). However, blocking of TLR2 had no effect on hydrogen peroxide-induced p38 phosphorylation after 15 min of treatment (Fig. 3b).

An Anti-apoptotic Role of TLR2 after Oxidative Stress in Cardiac Myocytes-- NF-kappa B activation can elicit anti-apoptotic and pro-apoptotic pathways in various cell types. Whether NF-kappa B promotes or inhibits apoptosis seems dependent on the type of cell and the type of inducer (27). Under the conditions of ischemic injury and oxidative stress, NF-kappa B appears to have an anti-apoptotic role in cardiac myocytes (28). To investigate the role of TLR2 in myocyte survival after oxidative stress, NRVM were preincubated with a blocking TLR2 antibody for 1 h and then treated with 0.5 mM hydrogen peroxide. The fraction of myocytes with DNA fragmentation, measured as the percentage of cells in sub-G1 phase, ranged from 6.9 to 10.9% under basal, serum-free conditions over the 6-h incubation. Hydrogen peroxide increased this number to 12 ± 4.6% at 30 min, to a maximum of 33.2 ± 5.9% at 6 h. Preincubation with the TLR2 antibody further increased hydrogen peroxide-induced DNA fragmentation at all time points examined, to a maximum of 40.5 ± 4.9% at 6 h. A nonimmune IgG was without effect (Fig. 4a) on the response to hydrogen peroxide.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   TLR2 has an anti-apoptotic/cytotoxic function. a, cells were treated with hydrogen peroxide (0.5 mM) for the indicated times in the absence or presence of TLR2 antibody or matched nonimmune antibody (NI). 10,000 cells per experimental group were analyzed for DNA fragmentation by quantitating the fraction of cells in sub-G1 phase by FACS. Pretreatment with the TLR2 antibody further increased hydrogen peroxide-induced DNA fragmentation. NI denotes a nonimmune rabbit IgG. Data were pooled from three to six separate experiments and are the mean sub-G1 populations. b, annexin V binding to NRVM following exposure to hydrogen peroxide (0.5 mM) in the presence or absence of TLR2 antibody or matched nonimmune antibody (NI IgG). Results are representative of two experiments with similar results; 10,000 cells/experimental group were analyzed by FACS.

Annexin V has a strong, specific affinity for phosphatidylserine (PS). Shortly after cells are induced into apoptosis, PS redistributes from the inner to the outer layer of the cell membrane, thus providing a readily detectable marker of dying cells (29). Basal levels of annexin V-positive cells in these experiments were found to be high, averaging ~25%. Hydrogen peroxide stimulation had no effect at 30 min but modestly increased annexin V staining of NRVM after 2 h incubation, to 35%. As shown in Fig. 4b, blockade of TLR2 increased the response to hydrogen peroxide at 30 min (H2O2, 25% versus H2O2+alpha -TLR2 Ab, 65%), and at 2 h (H2O2, 35% versus H2O2+alpha -TLR2 Ab, 46%). Pretreatment with a nonimmune IgG was without effect. Thus, blockade of TLR2 inhibits hydrogen peroxide-induced NF-kappa B and AP-1 activity but enhances hydrogen peroxide-induced DNA fragmentation and PS externalization in NRVM, suggesting an anti-apoptotic function of TLR2 in cardiac myocytes after oxidative stress.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The innate immunity system is an evolutionarily ancient and conserved form of the immune system that is triggered by soluble and membrane bound "pattern recognition receptors" (PRR). In the expanded self-nonself model of innate immunity, PRRs have evolved to distinguish between dangerous and innocuous nonself antigens. Therefore, innate immunity recognizes invariant patterns (i.e. pathogen-associated molecular patterns) shared by groups of microorganisms but not by host tissues (30, 31). A typical pathogen-associated molecular pattern would be bacterial lipopolysaccharides (LPS), for example. However, Matzinger (19, 32) has suggested a different explanation for function and triggers of the innate immune system. In the "Danger" model, the immune system would be activated by endogenous "alarm" or "danger" signals, which originate from stressed, injured, or necrotic cells and not by highly conserved structured motifs in pathogens. These danger signals are recognized by the pattern recognition receptors and activate the innate immune system. Therefore, PRRs of the innate immune system would recognize specific epitopes or ligands that indicate injured, dying, or dead cells (i.e. injured/dead self) even in the absence of infection. Signals of "stressed" cells could be sensed by changes in the lipid and/or carbohydrate moieties expressed on the surface of cells or by the presence of proteins not normally found in the outer cell membrane.

Increased myocardial expression of inflammatory cytokines, such as TNF, IL-1beta , and IL-6, occurs in human and experimental heart failure, seemingly irrespective of initiating events and without evidence of infection (33). Although there is a growing consensus that one or more of these proteins contribute to maladaptive cardiac remodeling, the proximal events that trigger and sustain their expression are not well understood. However, each of these cytokines is now known to be related to innate immunity, and their expression may be initiated through activation of specific innate immunity receptors. We have previously shown that TLR4 is expressed in cardiac myocytes and that overexpression of dominant positive TLR4 activates NF-kappa B. In normal murine and human myocardium, TLR4 expression was diffuse and predominantly expressed in cardiac myocytes. However, in both "remodeling" murine and human myocardium remote from sites of ischemic injury and in heart tissue from patients with idiopathic congestive heart failure, focal areas of intense TLR4 staining in myocytes could be detected (17). Therefore, pattern recognition receptors, as for example TLRs, may be important to trigger activation of the innate immune system in congestive heart failure and may have an important pathogenic role.

In this report, we provide evidence for a function of the TLR2 receptor, which is also expressed in unstimulated cardiac myocytes. Reactive oxygen species (ROS) are proposed to be a major pathogenic factor for hypoxic and ischemic damage in the heart. To confer oxidative stress in vitro, hydrogen peroxide was used in neonatal rat ventricular myocytes. Several lines of evidence are developed that document TLR2's role in the nuclear translocation of NF-kappa B after stimulation with hydrogen peroxide. First, hydrogen peroxide increased NF-kappa B activity and nuclear translocation in CHO cells that overexpress TLR2 but not in CHO cells that lack a functional TLR2 or that overexpress TLR4. Second, an anti-TLR2 antibody, but not a nonimmune IgG, abrogated hydrogen peroxide-induced activation of NF-kappa B and AP-1 in TLR2-overexpressing CHO cells and NRVM. Several experiments discount any nonspecific effect of the TLR2 antibody: 1) a single immunoreactive band was present in NRVM that corresponded to a band in CHO/TLR2 cell lysates, 2) TNFalpha -induced NF-kappa B and AP-1 activity was unaffected by the antibody, 3) DNA binding of the constitutive transcription factor OCT-1 was unaffected, and 4) hydrogen peroxide-induced phosphorylation of p38 MAPK was similarly unaffected by the TLR2 antibody. Thus, from these criteria, we suggest that hydrogen peroxide triggers NF-kappa B and AP-1 activation through a mechanism that involves TLR2.

Oxidative stress has long been known to induce NF-kappa B and has been thought to be crucial for NF-kappa B activation in the cell (reviewed in Ref. 21). However, the recently characterized IL-1 and TNF pathways activate NF-kappa B independent of ROS, and the activation of NF-kappa B by ROS seems to be distinct from IL-1 and TNF. Moreover, different cell types respond to H2O2 in different ways. The kinetics for NF-kappa B activation by H2O2 are slow and may therefore be characteristic for a secondary response of NF-kappa B to agents that induce stress. An exact pathway for NF-kappa B activation by ROS has not been characterized yet, but may involve direct phosphorylation of tyrosine at position 42 on Ikappa Balpha (reviewed in Refs. 21, 34, 35). The current results suggest an alternative pathway, whereby H2O2 activates a surface receptor, TLR2, which in turn triggers the signaling events that degrade Ikappa B and activate NF-kappa B. The IL1R-like pathway utilized by TLR2 to activate NF-kappa B has recently been reported (36).

What is the mechanism by which H2O2 activates TLR2? It seems unlikely that H2O2 would directly interact with TLR2 in a classical ligand/receptor complex. However, hydrogen peroxide can modify membrane components and is a known inducer of apoptosis and necrosis in cardiac myocytes (28, 37). We suggest that cell death or injury could have caused the release of one or more factors that interact with and activate TLR2. Such a mechanism complements the delayed time course of H2O2-induced NF-kappa B activation and is reminiscent of the "alarm" or "danger" signals that activate innate immunity as outlined by Matzinger (19). In support of this, a recent report demonstrated that endogenous heat shock protein 60 (HSP60) may function as a ligand for TLR4 (18). HSPs are known to induce NF-kappa B (38). Of note, we could demonstrate2 the release of HSP60 in the supernatant of cardiac myocytes treated with H2O2, thus verifying that H2O2 can elicit release of a potential TLR ligand in NRVM. Further experiments are necessary and currently underway to address this hypothesis.

What function could H2O2-induced activation of TLR have in cardiac myocytes? Nuclear translocation of NF-kappa B occurs following activation of TLR2 (36). NF-kappa B then directs transcription of a variety of genes, including those related to apoptosis (27). A pro-apoptotic role of TLR2 has been proposed in a monocytic cell line (39, 40). However, the function of NF-kappa B in cell death is highly dependent on the type of cell as well as the type of inducer (27). Blockade of TLR2 increased the rate of hydrogen peroxide-induced apoptosis and injury in NRVM, based on two independent measures of cytotoxicity and apoptosis, hypodiploidy and externalization of phosphatidylserine. Therefore, TLR2 may have an anti-apoptotic function in the heart. In heart failure as well as after myocardial infarction, necrosis and apoptosis have a major pathogenetic role in the development of ventricular dysfunction (41, 42). Considering that we have seen increased levels of TLR expression specifically in the border zones between viable and damaged myocardium after infarction (17),2 one could speculate that activation of TLRs play a role in the protection of ischemic but viable myocardium.

In summary, TLR2 participates importantly to the mechanism of hydrogen peroxide-induced activation of NF-kappa B and AP-1 in NRVM. We suggest that activation of TLR2 is triggered by hydrogen peroxide-generated endogenous signals that may increase survival of cardiac myocytes after oxidative stress.


    ACKNOWLEDGEMENTS

We thank Dr. D. T. Golenbock for the gift of the CHO cell lines, and Dr. Min-Ying Pu for excellent technical assistance.


    FOOTNOTES

* This work was supported by the Deutsche Forschungsgemeinschaft and by National Institutes of Health Grants HL52320 and HL36141.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115. Tel.: 617-732-5876; Fax: 617-732-5132; E-mail: tbourcier@rics.bwh.harvard.edu.

Published, JBC Papers in Press, November 16, 2000, DOI 10.1074/jbc.M009160200

2 S. Frantz, R. A. Kelly, and T. Bourcier, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: TLR, toll-like receptor; IL-1, interleukin-1; JNK, c-Jun NH2-terminal kinase; LPS, lipopolysaccharide; AP-1, activator protein-1; TNF, tumor necrosis factor; CHO, Chinese hamster ovary; NRVM, neonatal rat ventricular myocyte; RT-PCR, reverse transcriptase-polymerase chain reaction; bp, base pair(s); PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; FACS, fluorescence-activated cell sorting; EMSA, electrophoretic mobility shift assay; MAPK, mitogen-activated protein kinase; PS, phosphatidylserine; Ab, antibody; PRR, pattern recognition receptor; ROS, reactive oxygen species; HSP, heat shock protein.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Medzhitov, R., and Janeway, C., Jr. (2000) N. Engl. J. Med. 343, 338-344[Free Full Text]
2. Schuster, J. M., and Nelson, P. S. (2000) J. Leukoc. Biol. 67, 767-773[Abstract]
3. Rock, F. L., Hardiman, G., Timans, J. C., Kastelein, R. A., and Bazan, J. F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 588-593[Abstract/Free Full Text]
4. Takeuchi, O., Kawai, T., Sanjo, H., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Takeda, K., and Akira, S. (1999) Gene 231, 59-65[CrossRef][Medline] [Order article via Infotrieve]
5. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A., Jr. (1997) Nature 388, 394-397[CrossRef][Medline] [Order article via Infotrieve]
6. Muzio, M., Natoli, G., Saccani, S., Levrero, M., and Mantovani, A. (1998) J. Exp. Med. 187, 2097-2101[Abstract/Free Full Text]
7. Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C. J. (1999) J. Biol. Chem. 274, 17406-1749[Abstract/Free Full Text]
8. Brightbill, H. D., Libraty, D. H., Krutzik, S. R., Yang, R. B., Belisle, J. T., Bleharski, J. R., Maitland, M., Norgard, M. V., Plevy, S. E., Smale, S. T., Brennan, P. J., Bloom, B. R., Godowski, P. J., and Modlin, R. L. (1999) Science 285, 732-736[Abstract/Free Full Text]
9. Underhill, D. M., Ozinsky, A., Smith, K. D., and Aderem, A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14459-14463[Abstract/Free Full Text]
10. Hirschfeld, M., Kirschning, C. J., Schwandner, R., Wesche, H., Weis, J. H., Wooten, R. M., and Weis, J. J. (1999) J. Immunol. 163, 2382-2386[Abstract/Free Full Text]
11. Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., and Akira, S. (1999) J. Immunol. 162, 3749-3752[Abstract/Free Full Text]
12. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., and Beutler, B. (1998) Science 282, 2085-2088[Abstract/Free Full Text]
13. Qureshi, S. T., Lariviere, L., Leveque, G., Clermont, S., Moore, K. J., Gros, P., and Malo, D. (1999) J. Exp. Med. 189, 615-625[Abstract/Free Full Text]
14. Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., and Akira, S. (1999) Immunity 11, 443-451[Medline] [Order article via Infotrieve]
15. Arbour, N. C., Lorenz, E., Schutte, B. C., Zabner, J., Kline, J. N., Jones, M., Frees, K., Watt, J. L., and Schwartz, D. A. (2000) Nat. Genet. 25, 187-191[CrossRef][Medline] [Order article via Infotrieve]
16. Zhang, F. X., Kirschning, C. J., Mancinelli, R., Xu, X. P., Jin, Y., Faure, E., Mantovani, A., Rothe, M., Muzio, M., and Arditi, M. (1999) J. Biol. Chem. 274, 7611-7614[Abstract/Free Full Text]
17. Frantz, S., Kobzik, L., Kim, Y. D., Fukazawa, R., Medzhitov, R., Lee, R. T., and Kelly, R. A. (1999) J. Clin. Invest. 104, 271-280[Abstract/Free Full Text]
18. Ohashi, K., Burkart, V., Flohe, S., and Kolb, H. (2000) J. Immunol. 164, 558-561[Abstract/Free Full Text]
19. Matzinger, P. (1998) Semin. Immunol. 10, 399-415[CrossRef][Medline] [Order article via Infotrieve]
20. von Harsdorf, R., Li, P. F., and Dietz, R. (1999) Circulation 99, 2934-2941[Abstract/Free Full Text]
21. Bowie, A., and O'Neill, L. A. (2000) Biochem. Pharmacol. 59, 13-23[CrossRef][Medline] [Order article via Infotrieve]
22. Peng, M., Huang, L., Xie, Z. J., Huang, W. H., and Askari, A. (1995) Cell Mol. Biol. Res. 41, 189-197[Medline] [Order article via Infotrieve]
23. Lien, E., Sellati, T. J., Yoshimura, A., Flo, T. H., Rawadi, G., Finberg, R. W., Carroll, J. D., Espevik, T., Ingalls, R. R., Radolf, J. D., and Golenbock, D. T. (1999) J. Biol. Chem. 274, 33419-33425[Abstract/Free Full Text]
24. Bourcier, T. (1999) in Methods in Molecular Medicine, Vascular Disease (Baker, A. H., ed) , pp. 159-167, Humana Press, Totowa, NJ
25. Heine, H., Kirschning, C., Lien, E., Monks, B., Rothe, M., and Golenbock, D. (1999) J. Immunol. 162, 6971-6975[Abstract/Free Full Text]
26. Guyton, K. Z., Liu, Y., Gorospe, M., Xu, Q., and Holbrook, N. J. (1996) J. Biol. Chem. 271, 4138-4142[Abstract/Free Full Text]
27. Barkett, M., and Gilmore, T. D. (1999) Oncogene 18, 6910-6924[CrossRef][Medline] [Order article via Infotrieve]
28. Mustapha, S., Kirshner, A., De Moissac, D., and Kirshenbaum, L. A. (2000) Am. J. Physiol. Heart Circ. Physiol. 279, H939-H945[Abstract/Free Full Text]
29. Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D. M., and Green, D. R. (1995) J. Exp. Med. 182, 1545-1556[Abstract]
30. Janeway, C. A., Jr. (1992) Immunol. Today 13, 11-16[CrossRef][Medline] [Order article via Infotrieve]
31. Medzhitov, R., and Janeway, C. A., Jr. (1997) Cell 91, 295-298[Medline] [Order article via Infotrieve]
32. Matzinger, P. (1994) Annu. Rev. Immunol. 12, 991-1045[CrossRef][Medline] [Order article via Infotrieve]
33. Kapadia, S., Dibbs, Z., Kurrelmeyer, K., Kalra, D., Seta, Y., Wang, F., Bozkurt, B., Oral, H., Sivasubramanian, N., and Mann, D. L. (1998) Cardiol. Clin. 16, 645-656[Medline] [Order article via Infotrieve]
34. Flohe, L., Brigelius-Flohe, R., Saliou, C., Traber, M. G., and Packer, L. (1997) Free Radic. Biol. Med. 22, 1115-1126[CrossRef][Medline] [Order article via Infotrieve]
35. Muller, J. M., Rupec, R. A., and Baeuerle, P. A. (1997) Methods 11, 301-312[CrossRef][Medline] [Order article via Infotrieve]
36. Yang, R. B., Mark, M. R., Gurney, A. L., and Godowski, P. J. (1999) J. Immunol. 163, 639-643[Abstract/Free Full Text]
37. Turner, N. A., Xia, F., Azhar, G., Zhang, X., Liu, L., and Wei, J. Y. (1998) J. Mol. Cell Cardiol. 30, 1789-1801[CrossRef][Medline] [Order article via Infotrieve]
38. Kol, A., Bourcier, T., Lichtman, A. H., and Libby, P. (1999) J. Clin. Invest. 103, 571-577[Abstract/Free Full Text]
39. Aliprantis, A. O., Yang, R. B., Mark, M. R., Suggett, S., Devaux, B., Radolf, J. D., Klimpel, G. R., Godowski, P., and Zychlinsky, A. (1999) Science 285, 736-739[Abstract/Free Full Text]
40. Aliprantis, A. O., Yang, R. B., Weiss, D. S., Godowski, P., and Zychlinsky, A. (2000) EMBO J. 19, 3325-3336[Abstract/Free Full Text]
41. Anversa, P., Leri, A., Beltrami, C. A., Guerra, S., and Kajstura, J. (1998) Lab. Invest. 78, 767-786[Medline] [Order article via Infotrieve]
42. Haunstetter, A., and Izumo, S. (1998) Circ. Res. 82, 1111-1129[Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.